Building the divestiture case for a biopharma R&D platform.

Client context

The business context.

A generics biopharma company was considering the divestiture of an R&D platform and related assets. Leadership required a business case for the proposed portfolio decision.

The divestiture assessment needed to address the assets within the proposed transaction, their valuation and the alternatives for structuring a deal. These elements had to inform the same decision.

The work

How the engagement was delivered.

• Develop the divestiture business case

  Led development of the business case for the R&D platform and related assets, covering the proposed divestiture perimeter.

• Assess valuation and transaction alternatives

  Evaluated the assets and alternative deal structures as part of the divestiture assessment. Connected those alternatives with the business case presented for decision-making.

What changed

A business case for the portfolio decision.

The engagement delivered a divestiture business case covering the platform and related assets, valuation and alternative deal structures. The business case gave leadership a basis for evaluating the proposed transaction.